Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

20092,073 citationsJournal Articlebronze Open Access

Authors

Leslie M. Shaw · University of Pennsylvania

Hugo Vanderstichele · Fujirebio (Belgium)

Małgorzata Knapik-Czajka · University of Pennsylvania

Christopher M. Clark · Institute on Aging

Paul Aisen · University of California, San Diego

Ronald C. Petersen · Mayo Clinic

Kaj Blennow ·

Abstract

The CSF biomarker signature of AD defined by A beta(1-42) and t-tau in the autopsy-confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD.

Topics & Keywords

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research Schizophrenia research and treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Neurology

Volume 65, Issue 4, pp. 403-413

DOI: 10.1002/ana.21610

Field-Weighted Citation Impact: 70.18